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Abstract
In previous studies, we found that adenomatous polyposis coli (APC) blocks the base excision repair (BER) pathway
by interacting with 5′-flap endonuclease 1 (Fen1). In this study, we identify the molecular features that contribute to
the formation and/or stabilization of the APC/Fen1 complex that determines the extent of BER inhibition, and the
subsequent accumulation of DNA damage creates mutagenic lesions leading to transformation susceptibility. We
show here that APC binds to the nuclear localization sequence of Fen1 (Lys365Lys366Lys367), which prevents entry of
Fen1 into the nucleus and participation in Pol-β–directed long-patch BER. We also show that levels of the APC/Fen1
complex are higher in breast tumors than in the surrounding normal tissues. These studies demonstrate a novel role
for APC in the suppression of Fen1 activity in the BER pathway and a new biomarker profile to be explored to identify
individuals who may be susceptible to the development of mammary and other tumors.
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Introduction
The genomes of eukaryotic cells are under continuous attack by en-
dogenous and exogenous sources. Endogenous DNA damage arises
from chemical instability (depurination), oxygen free radicals, and mis-
incorporation of nucleotides by DNA polymerases, whereas exogenous
sources of DNA damage include environmental agents such as ultra-
violet radiation, ionizing radiation, and various genotoxic agents [1,2].
Persistence of DNA damage can lead to genomic instability, apoptosis,
or mutagenesis, which can eventually lead to carcinogenesis. Fortu-
nately, the cell has developed various DNA damage checkpoints and
DNA repair systems to deal with genomic insults.
DNA repair systems efficiently remove damaged DNA through
several pathways. Abasic DNA lesions account for a large percentage
of total DNA damage and are repaired through the base excision repair
(BER) system. The BER system is composed of two subpathways:
single-nucleotide BER, also referred to as short-patch (SP)-BER, and
multinucleotide BER, also referred to as long-patch (LP)-BER. A
DNA glycosylase recognizes the damaged base and cleaves the glyco-
sidic bond between the sugar and base leaving an apurinic/apyrimidinic
(AP) or abasic site [3,4]. DNA glycosylases can be monofunctional
or bifunctional. In the case of a monofunctional DNA glycosylase,
AP-endonuclease 1 (APE1) incises the 5′ end of the resulting AP site
to generate the free 3′-hydroxyl required by the repair polymerase.
Bifunctional glycosylases not only remove the aberrant base but also
cleave the AP site on the 3′ side. The remaining deoxyribose phosphate
(dRP) residue is then removed by APE1 [5]. Progress of the SP-BER
or LP-BER pathway depends on the type of DNA damage. During
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SP-BER, the dRP lyase activity of DNA polymerase β (Pol-β), which
is located in the 8-kDa domain of Pol-β, removes the 5′ dRP left be-
hind by APE1, generating a 5′ phosphorylated nicked DNA strand [6].
Pol-β then uses its polymerase activity, which is located in its 31-kDa
C-terminal domain, to insert the correct base at the site of damage. The
remaining nick is sealed by DNA ligase I [7].
Mutations in the adenomatous polyposis coli (APC ) gene are among
the earliest events leading to the development of colorectal cancer [8,9].
The APC gene, located on chromosome 5q21-q22, consists of 8535 nt,
and spans 21 exons. The APC gene encodes a 310-kDa protein, which
is composed of 2843 amino acids in its common isoform [10]. It is
present in both the cytoplasm and the nucleus. Approximately 75%
of the coding sequence is located on exon 15, which seems to be the
most common target for both germ line and somatic mutations of APC
[11]. The mutation cluster region (MCR) is located within codons
1280 to 1513 and harbors more than 60% of all somatic mutations
in the APC gene [12]. Mutations that occur in the MCR of APC result
in a truncated protein that lacks most of the C-terminus required for
proper APC function: the basic domain, which is the site of microtu-
bule binding, and binding sites for EB1 and hDLG [13]. APC is also
involved in Wnt signaling and β-catenin regulation, cell-cell adhesion,
apoptosis, cell migration, chromosomal instability, and cell cycle con-
trol [10,14–17].
Fen1 is a structure-specific nuclease that is pivotal in maintaining
genome stability through its involvement in DNA replication and re-
pair. Fen1 is essential for survival as Fen1-knockout in mice is em-
bryonic lethal. Mutations in Fen1 have been implicated in various
diseases including Huntington disease, myotonic dystrophy, and can-
cer [18,19]. Indeed, Fen1 may be a novel tumor suppressor [20,21].
In addition to its 5′-flap endonuclease activity, Fen1 also possesses
5′-3′ exonuclease activity, which is required for the removal of dis-
placed RNA-DNA primers during discontinuous lagging-strand repli-
cation and Okazaki fragment maturation [22,23]. Mutations in Fen1
increase genomic instability by causing chromosomal loss and accumu-
lation of toxic flaps [24], whereas abnormal expression of Fen1 may
cause defective BER and, thus, accumulation of mutations that can
lead to genomic instability [25,26].
In previous studies, we demonstrated that APC interacts with the
BER proteins Pol-β and Fen1 and that this interaction blocks BER
through three different mechanisms: (i) APC blocks BER by interact-
ing with Pol-β and blocking Pol-β–directed strand displacement
synthesis in LP-BER; (ii) APC interacts with Pol-β and inhibits its
deoxyribose phosphate (dRP) lyase activity, thus blocking SP-BER;
and (iii) APC interacts with Fen1, inhibiting its 5′-flap endonuclease
and 5′-3′ exonuclease activities, thus blocking LP-BER [27]. In pre-
vious studies, the effect of APC on BER was examined by using a
20-amino acid fragment of APC containing the DNA repair inhibi-
tory (DRI) domain in an in vitro reconstituted BER system [27–30].
In this report, we provide more detail on how APC interacts with
Fen1 and restricts its retention in cytoplasm to impair its participa-
tion in LP-BER in the nucleus of cultured breast and colon cancer
cell lines. These findings suggest that in normal colon and breast
epithelial cells the levels of wild-type APC levels are low and probably
do not interfere with Fen1 and thus LP-BER activity. However, after
treatment with environmental carcinogens cytoplasmic APC levels
increase, resulting in the retention of Fen1 in the cytoplasm as well
as sequestration of any nuclear Fen1 into the nucleolus. The combined
reduction in Fen1 level and sequestration of nuclear Fen1 inhibit
Fen1-mediated LP-BER. This inhibited or compromised LP-BER
ultimately results in accumulation of mutations leading to the trans-
formation of normal epithelial cells.
Materials and Methods
Yeast Cell Maintenance
The yeast strain PJ694-A was used for all yeast two-hybrid experi-
ments. The yeast strain PJ69-4A (MATa trp1-901 leu2-3,112ura3-
52 his3-200 gal4Δ gal80Δ GAL2-ADE2 LYS2::GAL1-HIS3 met2::
GAL7-lacZ) was grown on synthetic dropout medium lacking lysine
(0.17% Difco yeast nitrogen base without amino acids, ammonium
sulfate (5.0 g/L), complete supplemental amino acid mixture minus
appropriate amino acids containing 2% glucose).
Preparation of Nuclear and Cytoplasmic Fractions
The nuclear extract and cytoplasmic fractions were prepared by
the procedure described by Shapiro et al. [31]. APC, Fen1, lamin B,
α-actin, and GAPDH protein levels were determined by Western blot
analysis, as described in our previous studies [32].
In Vitro LP-BER Assay
The in vitro LP-BER assay reaction was composed of 2.5 nM APE1
nicked 32P-labeled 63-mer F-DNA, 5 μg of nuclear extract as a source
of BER proteins, and 20 μM dNTPs. F-DNA is an AP-site analog
(3-hydroxy-2-hydroxymethyltetrahydrofuran; noted as F) containing
substrate, in which the F is inserted at the 24th position of the DNA
oligomer [20]. The reaction was incubated at 37°C for 60 minutes after
which the products were separated on a 15% acrylamide/7 M urea
gel. The radioactive signals were visualized by autoradiography.
Immunohistochemistry of Breast and Colon Cancer Cell
Lines in Culture
Human breast cancer cell line MB231 was plated into six-well plates
containing sterilized coverslips. After 24 hours, cells were transfected
for 24 hours with flag-tagged pAPC(1338), pAPC(1309), pAPC
(1309mut), and pAPC(1211) plasmids using Lipofectamine transfec-
tion reagent (Invitrogen, Carlsbad, CA). One set of these cells without
any transfection was treated for 24 hours with 25 μM benzo[a]pyrene
(B[a]P). Similarly, HCT-116 and HCT-116-APC(KD) cells were
treated with different concentrations of methyl methanesulfonate
(MMS) for 24 hours. After transfection or treatment, cells were fixed
with paraformaldehyde and incubated with antimouse Alexa 488 and
antirabbit Alexa 594 antibodies (Invitrogen). Cells were washed and
mounted onto slides using Vectashield mounting medium containing
fluorescent 4,6-diamidino-2-phenylindole (DAPI) (Vector Laborato-
ries, Burlingame, CA). Slides were viewed under a Zeiss upright micro-
scope (Carl Zeiss Microscopy, Thornwood, NY) at wavelength 515 nm
for Flag-APC and 640 nm for Fen1.
Immunohistochemistry of Breast Cancer and
Normal Tissue Arrays
Human breast cancer tissue array slides were purchased fromBiomax,
Inc (Rockville, MD). Slides contained both normal and breast cancer
tissue embedded in paraffin. After deparaffinization, washed array slides
were blockedwith PBS containing 5% goat serum and 0.2%TritonX-100
and then incubated with mouse anti-Fen1 antibody (Abcam, Cambridge,
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MA) and rabbit anti-APC (Santa Cruz Biotechnology, Santa Cruz, CA)
in PBS containing 5% goat serum and 0.2% Triton X-100 for 2 hours.
The procedure for microscopic fluorescence signal detection was per-
formed as described for cells in culture.
APC Protein Fragments
A 20-amino acid fragment of APC protein (1250-KVSSINQETIQ-
TYCVEDTPI-1269), termed the DRI domain, was synthesized at the
Protein Chemistry and Biomarkers core facility at the Interdisciplinary
Center for Biotechnology Research of the University of Florida [28].
The sequence represents the DRI domain of wild-type APC (APCwt)
or a mutated form of APC, APC(I-A,Y-A), in which amino acids Ile1259
andTyr1262 were replaced with alanine (A). The amino acids Ile1259 and
Tyr1262 of the DRI domain are the site of interaction with Pol-β and
Fen1, located in the N-terminal region, and are spared by mutations
of mutator cluster region (MCR) that result in truncation of the APC
protein. Thus, most mutant APC proteins (those with an intact DRI
domain), as well as wild-type APC, are capable of modulating BER
[30]. We also cloned a longer APC protein expression (1-1309 aa) plas-
mid, which was generated from a natural nonsense mutation in colon
cancer patients [33,34]. The 1-1309-aa protein fragment retains the
DRI domain. We introduced mutations at residues I1259 and Y1262
of the DRI domain of this protein. An oligonucleotide containing
FLAG and the N-terminal APC coding sequence were fused and in-
serted into the pcDNA5/FRT/TO vector (Invitrogen) using Hind III
and XhoI sites (Table 1). This vector was used to introduce the APC
(1-1309) coding plasmid into the BamHI and XhoI sites. BamHI and
XhoI sites, which contained the start sequence of APC and the stop
codon, respectively, were introduced in the APC complementary
DNA (cDNA) by polymerase chain reaction (PCR) amplification.
The upstream APC sequence was fused to the FLAG region and the
oligonucleotide to introduce the stop codon in APC(1-1309) is shown
in Table 1. The truncated APC construct carries a silent substitution at
codon 1120G to introduce an NcoI site for efficient cloning. All PCR-
amplified sequences were confirmed by direct sequencing.
Structure of DNA Used for the Synthesis of Fen1 Protein
Fragments for Transcription/Translation Assays
To identify the APC-binding site of Fen1, different Fen1 cDNA
constructs were made for transcription/translation (TNT) assays.
Fen1 protein fragments were expressed using the in vitro transcrip-
tion/translation system and then the interaction of APC and Fen1
was analyzed by far-Western analysis. Primers for each protein frag-
ment were designed to include a T7 promoter and a Kozak sequence
in the sense primer and a stop codon and poly A tail in the antisense
primer. Five fragments of Fen1 were designed (amino acids 1-115,
78-192, 154-268, 231-345, and 269-380). The primers used to
generate the protein fragments are shown in Table 1.
Site-Directed Mutagenesis of Fen1
Two sets of Fen1 mutants (set 1: K354A/R355A/K356A and set 2:
K365A/K366A/K367A) were generated using the QuickChange Site–
directed mutagenesis kit (Stratagene, La Jolla, CA). The primer pairs
used to generate set 1 and set 2 mutants are shown in Table 1.
Table 1. Oligonucleotide Sequences for Different Primers and Substrates for Fen1.
Experiment Oligonucleotide Sequence
(1) TNT assay
Fragment 1-115
Sense primer 5′-TAATTTTAATACGACTCACTATAGGGAACAGCCACCATGGGAATTCAAGGCCTGGCC-3′
Antisense primer 5′-TTTTTTTTTTTTTTTTTTTTTTTTTTTTTACTGAGCCTGCTGCAGCTGCTTCTCTGCCTC 3′
Fragment 78-192
Sense primer 5′-TAATTTTAATACGACTCACTATGGGAACAGCCACCATGGGCATCAAGCCCGTGTAT-3′
Antisense primer 5′-TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTATCGCATTAGCACAGGGCTGCCGAACCT-3′
Fragment 154-268
Sense primer 5′-TAATTTTAATACGACTCACTATAGGGAACAGCCACCATGGATGCACCCAGTGAGGCA-3′
Antisense primer 5′-TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTAAGGGTACTTGTTGGGGTCAAGTCGCAC-3′
Fragment 231-345
Sense primer 5′-TAATTTTAATACGACTCACTATAGGGAACAGCCACCATGGGCAGTGACTACTGTGAGAGT-3′
Antisense primer 5′-TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTACTTGAAGAAATCATCCAGGCGGCCCTGGGT-3′
Fragment 269-380
Sense primer 5′-TAATTTTAATACGACTCACTATAGGGAACAGCCACCATGGTGCCAGAAAATTGGCTCCAC-3′
Antisense primer 5′-TTTTTTTTTTTTTTTTTTTTTTTATTTTCCCCTTTTAAACTTCCCTGCTGCCCCAGTCTTTGC-3′
(2) Site-directed mutagenesis
Set 1 mutant (Set 1 primer pair 1)
Sense primer 5′-GGCTCACTCTCTTCAGCTGCGCGCGCAGAGCCAGAACCCAAGGGATCC-3
Antisense primer 5′-GGATCCCTTGGGTTCTGGCTCTGCGCGCGCAGCTGAAGAGAGTGAGCC-3′
Set 1 mutant (Set 1 primer pair 2)
Sense primer 5′-GGCTCACTCTCTTCAGCTGCGGCCGCAGAGCCAGAACCCAAGGGATCC-3′
Antisense primer 5′-GGATCCCTTGGGTTCTGGCTCTGCGGCCGCAGCTGAAGAGAGTGAGCC-3′
Set 2 mutant (Set 2 primer pair 1)
Sense primer 5′-GAACCCAAGGGATCCACTGCGAAGGCCGCAAAGACTGGGGCAGCA-3′
Antisense primer 5′-TGCTGCCCCAGTCTTTGCGGCCTTCGCAGTGGATCCCTTGGGTTC-3′
Set 2 (Set 2 primer pair 2)
Sense primer 5′-GAACCCAAGGGATCCACTGCGGCAGCCGCAAAGACTGGGGCAGCA-3′
Antisense primer 5′-TGCTGCCCCAGTCTTTGCGGCTGCCGCAGTGGATCCCTTGGGTTC-3′
(3) FEN1 activity
23-mer upstream 5′-CTAGATGCCTGCAGCTGATGCGC-3′
51-mer downstream 5′-AACATTFTTTTTGTACGGATCCACGTGTACGGTACCGAGGGCGGGTCGACA-3′
63-mer complementary 5′-AGATGCCTGCAGCTGATGCGCGGTACGGATCCACGTGTACGGTACCGAGGGCGGGTCGACA-3′
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Synthesis of Fen1 Protein Fragments, Fen1wt, and Fen1mut
Proteins Using an In Vitro Transcription/Translation System
Fen1 protein fragments, NLS1mut, NLS2mut, and Fen1 wild-
type proteins were synthesized using the TNT PCR Quick Kit from
Promega (Madison, WI). The reaction was run per the instructions
provided with the kit. The TNT-synthesized Fen1 protein fragments
were analyzed with Western blot [23].
Far-Western Blot Analysis
APCwt and APC(I-A,Y-A) peptides were slot-blotted (0-15 μg)
onto a polyvinylidene difluoride (PVDF) membrane (GE Healthcare,
Piscataway, NJ) in a binding buffer containing 20 mM Tris-HCl at
pH 7.4, 100 mM phosphate buffer at pH 7.4, 60 mM KCl, and
0.25% (vol/vol) Nonidet P-40 [27]. After blot analysis, the membrane
was blocked with 5% (wt/vol) bovine serum albumin and washed
three times with Tris-buffered saline with 0.025% (vol/vol) Tween-
20 before incubating with in vitro TNT-synthesized human Fen1 pro-
tein fragments (described above), wild-type, NLS1mut [Fen1(K354A/
K355A/K366A)], and NLS2mut [Fen1(K365A/K366A/K367A)]
proteins. Binding was detected using mouse anti-Fen1 antibody
(Novus Biologicals, Littleton, CO). The signals were detected using
the enhanced chemiluminescence reagent (GE Healthcare).
Pull-down of Fen1 Wild-type and Fen1(K365A/K366A/
K367A) Proteins from the Transcription/Translation
Synthesis Reaction Mixture
Fen1wt and Fen1(K365A/K366A/K367A) mutant were pulled
down by incubating with rabbit antihuman Fen1 antibody in immu-
noprecipitation buffer (30 mMHEPES at pH 7.5, 30 mMKCl, 8 mM
MgCl2, 0.01% NP-40, and 2% glycerol) for 4 hours followed by the
addition of 5% bovine serum albumin blocked Protein A Sepharose
beads (Promega) for an additional 2 to 3 hours. Beads were washed
three times with 30 mM HEPES at pH 7.5, 30 mM KCl, and 5%
glycerol and then resuspended in reaction buffer and used for Fen1
activity assays or Western blot analysis.
Synthesis and Labeling of the Fen1 Substrate
The Fen1 substrate for 5′-flap endonuclease activity was synthesized
as described in Table 1 [35]. The 51-mer downstream oligonucleotide
has a flap of 11 nt. The Fen1 substrate for 5′-3′ exonuclease activity
was made similarly except that the 11-nt flap from the 51-mer oligo-
nucleotide was removed. The 51- and 40-mer downstream oligo-
nucleotides were radiolabeled at the 5′ end with [γ-32P]ATP using
T4 polynucleotide kinase (New England Biolabs, Woburn, MA). After
annealing with a 63-mer complementary template as described in
Table 1, the labeled and annealed probes were purified by using a
nick column (GE Healthcare). All the three oligonucleotides were
annealed at a molar ratio of 1:1:1.
Fen1 Activity In Vitro
The assays for Fen1 5′-flap endonuclease and 5′-3′ exonuclease
activities were performed in a final volume of 20 μl. The reaction mix-
ture contained 30 mMHEPES at pH 7.5, 30 mMKCl, 8 mMMgCl2,
1 mM dithiothreitol, 200 μg/ml bovine serum albumin, and the in-
dicated amounts of Fen1 or Fen1(K365A/K366A/K367A) mutant.
Then, 2.5 nM 32P-labeled flapped-DNA or nicked-DNA substrates
were added to the reaction mixture and incubated at 37°C for 30 min-
utes. Reactions were terminated with stop solution containing 0.4%
(wt/vol) SDS and 5 mM EDTA. The DNA was recovered by phenol/
chloroform extraction followed by ethanol precipitation. The 11-nt
DNA product from the 5′-flap endonuclease activity and 1-nt prod-
uct from the 5′-3′ exonuclease activity were separated on a 15% acryl-
amide and 7 M urea gel and quantified by electronic autoradiography
(InstantImager; Packard Instrument Co, Meriden, CT). Statistical analysis
(n = 3) was performed using a t-test in SigmaPlot 12 graphing software.
Results
Nuclear Extracts with Higher Levels of Endogenous APC
Are Less Competent in LP-BER
To establish the role of endogenous wild-type APC in blocking
BER, we established an in vitro BER assay system with purified
nuclear extracts (NEs) of MB231 and MB468 breast cancer cell lines.
The MB231 cell line expresses a low level of APC, whereas the MB468
cell line expresses a high level of APC (Figure 1A, compare lane 1 with
lane 2) [31]. We also knocked down the APC level in MB468 cells
with pShRNA-APC [27,29,36,37]. We performed an LP-BER assay
with these nuclear extracts (Figure 1B). Results of the LP-BER assay
showed a protein concentration-dependent increase in LP-BER ac-
tivity, which was higher with MB231-NE thanMB468-NE (Figure 1C ,
compare lanes 3-6 with 8-11). Once we knocked-down APC in MB468
cells, the MB468-(pShRNA-APC)-NE exhibited higher LP-BER ac-
tivity than MB468-NE (Figure 1C , compare lanes 8-11 with 13-16).
These results clearly support our hypothesis that the presence of wild-
type APC inhibits LP-BER.
Overexpression of Truncated APC(1-1309) with and
without Mutations at the DRI Domain Impairs Nuclear
Localization of Fen1
In previous studies, we reported that the interaction of APC with
Fen1 is necessary to block LP-BER [27]. In this study, we examined
the mechanism by which APC interaction with Fen1 might perform
this role. To gain a better understanding about the role of the func-
tional interaction of APC with Fen1, we performed immunofluo-
rescence analysis to examine colocalization in the MB231 breast
cancer cell line, which expresses low levels of APC.We transiently over-
expressed flag-tagged truncated APC(1-1309; amino acids 1-1309)
protein. APC(1-1309) retains the DRI domain (amino acids 1245-
1273), a critical region where Fen1 interacts with APC [27]. The
APC(1-1309mut) contains alanine substitutions at amino acid residues
I1259 and Y1262, which are important for the interaction with Fen1
[27]. Amino acids 1-1309 are a naturally occurring truncation of APC
found in colorectal cancers [38].
After 24 hours of transfection, colocalization of APC and Fen1 was
determined by immunostaining with anti-APC and anti-Fen1 anti-
bodies. We found a higher cytoplasmic and some nucleolar localization
of overexpressed truncated APC proteins inMB231 cells compared with
the control cells (Figure 2, A and B). Localization of APC(1-1309) in
the cytoplasm and nucleolus was consistent with previous observations
[33,39,40]. Punctate staining of APC(1-1309) can be seen in the cyto-
plasm, but it is not visible at the edges of the cells, probably because
of the lack of the C-terminal end of APC(1-1309), which has the
EB1-binding sequence necessary for microtubule association [41].
Fen1 showed decreased nucleolar and diffuse cytoplasmic staining with
increased interaction with APC(1-1309) (Figure 2A).
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Treatment with DNA-Damaging Agent B[a]P and/or
MMS Increases the Interaction of APC with Fen1 in
the Cytoplasm and Impairs Nuclear Translocation in
Breast and Colon Cancer Cell Lines
B[a]P is a potent breast carcinogen [42–44]. To mimic the APC
overexpression conditions, we treated MB231 breast cancer cells with
25 μM B[a]P for 24 hours and then determined the colocalization
of APC and Fen1. Results showed increased cytoplasmic levels of
endogenous APC in B[a]P-treated cells compared with controls
(Figure 2C , compare lower panel with upper panel ). In control cells,
Fen1 localization was diffuse and mainly localized in the nucleolus.
However, after B[a]P treatment, the level of Fen1 increased in both
cytoplasm and nucleolus with increased colocalization with APC
(Figure 2C , compare lower panel with upper panel ).
To further confirm our findings that APC blocks translocation of
nuclear Fen1, we used colon cancer cell lines HCT-116 (expressing
either wild-type APC) or HCT-116-APC(KD) (APC knockdown by
means of stable expression of pShRNA-APC) [29]. These cells were
treated with 500 μM of MMS, which causes methylation DNA dam-
age that is repaired by BER [45]. After treatment, cells were processed
either for immunofluorescence or for Western blot analysis. The im-
munofluorescence data with HCT-116 cells containing wild-type APC
showed an increased colocalization of APC and Fen1 in the cytoplasm
after MMS treatment. The nuclear APC and Fen1 levels were reduced,
and if present, they were localized in the nucleolus (Figure 3). Con-
versely, in HCT-116-APC(KD) cells, the translocation of nuclear
Fen1 was not affected after MMS treatment (Figure 3), suggesting
that, in the absence of APC, Fen1 is not sequestered in the cytoplasm.
Next, we confirmed the immunofluorescence data by Western blot
analysis. We treated HCT-116 and HCT-116-APC(KD) cell lines
with different concentrations of MMS and examined cytosol and
nuclear extracts for APC and Fen1 protein levels after MMS treat-
ment. APC protein level increased in a dose-dependent fashion with
a greater increase in cytosol than in nucleus (Figure 3B, compare lanes
1-5 with lanes 11-15, respectively). Concomitantly, cytosolic Fen1 pro-
tein decreased in nuclear extracts but not in the cytoplasmic fraction
(Figure 3B, compare lanes 1-5 with lanes 11-15, respectively). As ex-
pected, in HCT-116-APC(KD) cells the nuclear Fen1 level increased
after MMS treatment compared with HCT-116 cells (Figure 3B,
compare lanes 16-20 with lanes 11-15). These results indicate that
APC interrupts the entry of Fen1 to the nucleus after MMS treatment.
Reduced Levels of APC Increase Nuclear Fen1 Levels and
LP-BER Activity
Because wild-type and truncated APC(1-1309) shuttles between
cytoplasm and nucleus [33], overexpression of APC(1-1309) in trans-
fected colon cancer cells may limit our conclusion with regard to
colocalization. Therefore, we returned to MB468 breast cancer cell
line, which expresses high levels of APC without transfection of for-
eign genetic material, depleted endogenous APC by knockdown with
pSiRNA-APC, and prepared cytoplasmic and nuclear (combined
Figure 1. Nuclear extracts with increased APC protein levels have decreased LP-BER activity. (A) Western blot analysis of APC with purified
nuclear extracts ofMB231,MB468, andMB468-pSiRNA-APC cells. (B) Protocol for LP-BERwith purified nuclear extracts. The in vitro LP-BER
reaction was assembled by the addition of 5 μg of nuclear extract from pShRNA-APC knockdown and wild-type APC cells followed by the
addition of 20 μM dNTPs and 32P-F-DNA substrate. (C) Autoradiogram of LP-BER. The nuclear extracts from these cell lines (0, 0.5, 1.0, 1.5,
and 2.0 μg) were assembled with APE precut 32P-F-DNA and dNTPs and incubated for 90 minutes at 37°C. Lanes 1 and 2 show uncut and
APE cut 63-mer 32P-labeled F-DNA. Data are representative of two independent experiments.
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nucleolar and nuclear plasma fraction) extracts. We determined the
levels of APC and Fen1 by Western blot and performed BER assays
(Figure 4). The results indicate that 1) transfection with pSiRNA-APC
reduces the levels of APC in both the cytoplasm and nucleus (by 80%
and 65%, respectively; Figure 4, A and B, compare lanes 1 and 3 with
lanes 2 and 4), 2) the reduced level of APC was associated with altered
levels of Fen1 in both fractions, with decreased Fen1 in the cytoplasm
and increased Fen1 in the nucleus (Figure 4, A and C , compare lane 2
with lane 4), and 3) the increased nuclear Fen1 after APC knockdown
was associated with increased Fen1-mediated LP-BER (Figure 4D,
compare lanes 3 and 4). The decreased level of Fen1 in the cytoplasm
of APC knockdown MB468 cell extract was evident and a significant
increase in nuclear Fen1 was observed after APC knockdown (Figure 4,
A and C , lanes 3 and 4). These results suggest that APC knockdown
results in the decreased level of nuclear Fen1.
Mapping of Fen1 for Interaction with APC
To identify the Fen1 amino acid residues that might be important
for interaction with APC, we synthesized six different overlapping
fragments: 1-380 aa (wild-type), 1-115 aa, 78-192 aa, 154-268 aa,
231-345 aa, and 269-380 aa. Synthesis of the protein fragments was
confirmed byWestern blot analysis. The interaction of Fen1 fragments
with APC was determined by far-Western analysis. The Fen1 protein
fragments of amino acids 1-380, 78-192, 154-268, and 269-380 inter-
acted with the APCwt fragment but not with the APC(I-A,Y-A) mu-
tant fragment (Figure 5). These results suggested that APC interacts
with Fen1 fragments 78-192 and 154-268, which are part of Fen1’s
nuclease domain with an additional site outside the nuclease domain
at residues 346-380.
APC Interacts with the Nuclease Domain of Fen1
To observe the interaction of APCwith Fen1 at amino acids 154-268
directly, we used the yeast two-hybrid (Y2H) assay. Because Fen1 amino
acid residues Glu160 and Asp181 are important for its nuclease activity
[46] and interaction with APC blocks this activity, we reasoned that
the APC interaction might occur near these residues. We introduced
mutations E160Q and D181N into Fen1 and assessed the mutant
proteins for interaction with APC. Full-length and mutant Fen1 were
Figure 2. Colocalization of APC(1-1309) and Fen1 in MB231 cells after treatment with B[a]P. (A and B) Cells were transfected with flag-
pAPC(1-1309) or flag-pAPC(1-1309mut) plasmids for 24 hours. MDA-MB231 cells were stained for APC (Alexa-594, red) and Fen1 (Alexa-
488, green). The localization of flag-APC and Fen1 was determined by fluorescence microscopy. Images were merged to determine the
colocalization of these proteins. Data are representative of three independent experiments. (C) Immunofluorescence analysis of wild-
type APC and Fen1 colocalization in MB231 cells treated with B[a]P. Cells were treated with 25 μM B[a]P for 24 hours. The colocalization
of endogenous APC and Fen1 was determined by fluorescence microscopy. Images were merged to determine the colocalization of
these proteins. Data are representative of three independent experiments.
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cloned into the Y2H vector pGAD-C3. The APCwt fragment, which
contained the DRI domain (amino acids 1190-1328), and the APC
mutant (mut) fragment, which contained a mutated DRI domain
(amino acids 1200-1324 with I1259A and Y1262A mutations) were
cloned into the Y2H vector pGBDU-C3 (Figure 6A). The D181N
mutation abolished Fen1-APC interaction; however, the E160Q mu-
tated protein retained strong binding (Figure 6B). The Fen1(E160Q)
mutant, which retains wild-type–like binding ability, but partial cata-
lytic activity, exhibited strong APC binding, indicating that mutation
of Fen1 at Glu160 retains the ability to interact with APC. The inter-
action of PCNA and Pol-β was used as a positive control, whereas the
APC binding domain was used as a negative control to check for back-
ground colony formation in Y2H assays.We verified the Y2H results by
far-Western analysis. We purified His-tagged wild-type Fen1 and
mutant Fen1(D181N) proteins and blotted them against wild-type
(1250-1269 aa) and mutant (1250-1269 aa with I1259A and
Y1262A substitutions) APC peptides. The results showed increased
binding of Fen1 with wild-type (APCwt) but not with the APC(I-A,
Y-A) fragment (Figure 6C ). Fen1 (D181N) showed drastically reduced
binding activity with APCwt and no binding activity with APC(I-A,Y-
A) peptides (Figure 6C). These results indicate that Asp181 in the nucle-
ase domain of Fen1 is critical for interaction with APC; however, the
remaining poor binding exhibited by Fen1(D181N) indicated the pres-
ence of an additional binding site that might also be involved in the
Figure 3. Colocalization of wild-type APC and Fen1 in HCT-116 cells after treatment with MMS. (A) HCT-116 and HCT-116-APC(KD) cells
were treated with 500 μMMMS for 24 hours. Cells were stained for APC (Alexa-594, red), Fen1 (Alexa-488, green), and heterochromatin
(DAPI, blue). The localization of flag-APC, Fen1, and heterochromatin was determined by fluorescence microscopy. Images were
merged to determine the colocalization of these proteins. Data are representative of three independent experiments. (B) Western blot
analysis. Cells were treated with 0, 50, 100, 250, and 500 μM MMS for 24 hours. The cytoplasmic and nuclear fractions were prepared
and used for the determination of APC and Fen1 levels. β-Actin and lamin B levels were determined for protein loading normalization
and for identifying potential cross-contamination of the cytoplasmic and nuclear fraction preparations. Data are representative of two
independent experiments.
Neoplasia Vol. 14, No. 6, 2012 Functional Interaction of APC and Fen1 Jaiswal et al. 501
interaction with APC. These results show that APCwt interacts with
Fen1 in vivo at specific residues.
APC Interacts with the Nuclear Localization Signal
Domains of Fen1
Next, we identified the residues in the Fen1 346-380 fragment that
interacted with APC in the far-Western analysis (Figures 5 and 6). The
most striking feature of these residues is that most of them form part of
the Fen1 nuclear localization signal (NLS) [21]. Several other proteins
including Werner protein (WRN), Bloom syndrome protein (BLM),
and endonuclease G (EndoG) interact with Fen1 at residues 353-380
[47,48], which overlaps the region that interacts with APC, accord-
ing to far-Western analysis [27]. On the basis of the previously men-
tioned information, we mutated two sets of Fen1 residues (NLS1 =
Lys354Arg355Lys356 and NLS2 = Lys365Lys366Lys367) to determine
whether they participated in the interaction of Fen1 with APC. Each
set was chosen for its importance in nuclear localization, which was
located in the same region as that identified for the interaction of
Fen1 with WRN, BLM, and EndoG. Each amino acid was substituted
with alanine and the Fen1 mutants were synthesized using the TNT-
PCR Quick Kit. Binding of Fen1 (NLS1mut) and Fen1 (NLS2mut)
was determined by far-Western analysis. Both Fen1 (NLS1mut) and
Fen1 (NLS2mut) showed reduced binding to the APCwt peptide
fragment (Figure 7, A and B). The remaining binding of APC to Fen1
(NLS1mut) and Fen1 (NLS2mut) could have been due to its inter-
action with the nuclease domain (Asp181). These results suggest that
APC interacts with both the nuclease and the NLS domains of Fen1.
Fen1 (NLS2mut) Retains Catalytic Activity
Fen1 (NLS2mut) bound APC to a lesser extent than Fen1
(NLS1mut). Because previous experiments showed that APC blocks
Fen1 catalytic activity [27] we examined the effect of APC-Fen1
(NLS2mut) interaction on Fen1 catalytic activity using a 32P-labeled
flapped substrate. To use the TNT-synthesized Fen1wt and Fen1
(NLS2mut) for these assays, the proteins were immunoprecipitated
using an anti-Fen1 antibody (Figure 8A). Protein levels were deter-
mined by Western blot analysis (Figure 8B). Equal amounts of
Fen1wt or Fen1 (NLS2mut) proteins bound with beads were then
Figure 4. APC knockdown increases Fen1 levels and activity in the
nucleus. APC knockdown in MB468 breast cancer cells was accom-
plished by transfection with pSiRNA-APC, as shown in Figure 1.
(A) The cytoplasmic and nuclear fractions were prepared and used
for the determination of APC and Fen1 levels. GAPDH and lamin B
protein levels were determined for protein loading normalization
and for identifying potential cross-contamination of the cytoplasmic
and nuclear fraction preparations. (B and C) Quantitative analysis of
APC and Fen1 proteins levels. (D) The nuclear extract was also used
for the determination of LP-BER. Lanes 1 and 2 show 32P-labeled
63-mer F-DNA and APE1 incised 23-mer product, respectively. Data
shown are representative of two independent experiments.
Figure 5. Interaction of APC and Fen1 protein fragments. APCwt and
APC(I-A,Y-A) protein fragments were immobilized on a PVDF mem-
brane and incubated with either wild-type or fragments of Fen1 pro-
tein as indicated. Equal amounts of TNT-synthesized proteins were
used. Data are representative of three different determinations.
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used in the endonuclease reaction. The 5′-flap endonuclease activity
of Fen1wt and Fen1 (NLS2mut) was determined by the presence of
an 11-nt product. Interestingly, the Fen1(NLS2mut) cleaved the
5′-flap endonuclease substrate as efficiently as the wild-type protein
(Figure 8C , compare lanes 7-9 to lanes 10-12) indicating that muta-
tions in Fen1 at K365/K366/K367 are not important for 5′-flap
endonuclease activity.
The 5′-3′ exonuclease activity of Fen1 (NLS2mut) was also tested.
To determine the effect of APC on Fen1 exonuclease activity, a nicked
DNA substrate was used. We labeled the 63-mer nicked substrate with
γ-32P[ATP] as described previously [27]. Fen1wt and Fen1 (NLS2mut)
proteins were pulled down from the TNT reaction mixture as described
previously. Beads with bound Fen1wt or Fen1 (NLS2mut) were used
to assay exonuclease activity, which was determined by the appearance
of a 1-nt product. Surprisingly, the Fen1 (NLS2mut) had more 5′-3′
exonuclease activity than the wild-type protein (Figure 8D, compare
lanes 4 and 5 to lanes 6 and 7). These results indicate that the muta-
tions in Fen1 at amino acids Lys365Lys366Lys367 are important for
regulating its catalytic activity and ensuring that Fen1 does not remove
nucleotides adjacent to the primary cleavage site. Therefore, APC
binding to Fen1 Lys365Lys366Lys367 may block Fen1 activity by induc-
ing a conformational change. Alternatively, the large size of APC may
create steric hindrance.
Clinical Significance of APC and Fen1 Interaction in
Breast Cancer
We used Oncomine’s gene search function to locate microarray
studies of expression of APC and Fen1 in breast cancer (https://
www.oncomine.com). Oncomine processes and normalizes each
dataset independently. For differential expression analysis, we used
t statistics with false discovery rates as a corrected measure of sig-
nificance. We sorted the results based on each class of analysis, noted
the significance number of the studies produced, and then created a
box plot. These microarray values were preprocessed for normaliza-
tion by Oncomine. We compared the data from different studies and
found that both APC and Fen1 gene expressions were significantly
increased in breast carcinoma in comparison to adjacent normal or
benign tissues (data not shown). Although these results could have
major implications for the role of APC and Fen1 in breast tumori-
genesis, their utility is limited because the available data do not in-
clude information about variables, such as age and ethnicity, and
confounding factors, such as smoking status, alcohol use, and epide-
miologic health disparity information such as socioeconomic status.
Then, we examined whether the increased APC and Fen1 mRNA
levels were associated with increased protein levels and whether the
proteins colocalized in breast tumor tissues. We obtained breast can-
cer tissue arrays from US Biomax, Inc (Rockville, MD) containing
eight normal tissues, eight invasive ductal carcinoma, and four each
of lobular and mucinous carcinoma. We performed multicolor label-
ing of normal and tumor samples using highly specific APC and
Fen1 antibodies and determined their colocalization by fluorescence
microscopy. Results showed increased colocalization of APC and
Fen1 (yellow color in merged samples) in both invasive ductal carci-
noma and invasive lobular carcinoma in comparison to normal breast
tissues (Figure 9). Colocalization was increased in seven of the eight
invasive ductal carcinomas and all four invasive lobular carcinomas;
however, colocalization failed to occur in any of the mucinous carci-
nomas (data not shown). Although the number of samples examined
in the present study was limited, the results warrant future studies
with larger samples to establish a stronger link between APC/Fen1
interaction and DNA damage-induced breast carcinogenesis.
Discussion
In this report, we present data showing that APC regulates LP-BER
by controlling access of Fen1 to the nucleus as well as by sequestering
Figure 6. Interaction of APC with Fen1 by a yeast two-hybrid system. (A) Structure of APC and Fen1 constructs. The mutated amino acid
residues I and Y with A are shown with italics. (B) Yeast two-hybrid analysis of APC and Fen1 interaction. (C) Far-Western analysis of APC
and Fen1 showing that the D181N mutation in Fen1 reduces APC binding. Data are representative of three independent experiments.
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any nuclear Fen1 into the nucleolus. APC interacts with Fen1 at
Fen1’s two nuclear localization sequences (NLS1 and NLS2), which
provides the rationale for failure of the complex to transit the nuclear
envelope. However, the NLS sequences serve dual roles, the second
being to prevent Fen1 from acting as a nonspecific endonuclease.
This is the first report of APC regulating Fen1’s cellular localization,
which is an extension of previous work that identified an interaction
between APC and Fen1 [27,29,30].
Knockdown of wild-type APC with a pShRNA-APC plasmid
increases the nuclear pool of Fen1 and results in increased LP-BER
activity and decreases DNA damage [36]. Here we show, that in
contrast, exposure to genotoxic agents (DNA alkylating agents) or
carcinogens results in overexpression of APC and increased DNA
damage. These results are consistent with plasmid-based LP-BER
assay system in cell culture [36]. Thus, based on our present and
previous results, we conclude that the increased levels of APC as-
sociate with and block the entry of Fen1 to the nucleus, resulting
in decreased LP-BER.
In vitro studies with purified proteins showed that APC interacts
with two regions of Fen1 nuclease: the nuclease domain involving
Asp181 and NLS domains NLS1 and NLS2 at the carboxyl terminus
of the protein. Mutation at the nuclease domain (D181N) abolished
Fen1 catalytic activity [49], whereas mutations at the NLS1 and
NLS2 domains had no effect on catalysis but impaired nuclear local-
ization. Our results using fluorescence microscopy further suggested
that the interaction of APC with the NLS1 and NLS2 of Fen1 im-
pairs nuclear translocation and makes it unavailable for LP-BER.
APC forms complexes through distinct domains with a variety of
proteins in addition to Fen1. APC complexes with topoisomerase IIa
at APC residues 1000-1326; participates in the G2/M transition by
directly interacting with DNA through C-terminal residues 2140-
2421, which inhibits replication and prevents cell cycle progression
into or through S-phase; complexes with DNA PKcs through APC
residues 1441-2077, which enhances the early response to DSB re-
pair; and interacts with Pol-β and Fen1 to promote LP-BER. The
formation of different protein/protein complexes through different
Figure 7. Interaction of APC with NLS domains of Fen1. (A) Far-Western analysis of the interaction of APC with Fen1wt, Fen1 (NLS1mut),
and Fen1 (NLS2mut) protein fragments. APCwt and APC(I-A,Y-A) peptides were immobilized on a PVDF membrane and incubated with
either wild-type or fragments of Fen1 protein as indicated. (B) Percent binding of APCwt with Fen1 wild-type and mutant proteins. Percent
binding was determined by using the density of APC and Fen1 wild-type binding band as 100% binding and comparing Fen1 mutant
proteins and APC binding to the density of the APC and Fen1 wild-type band [(density of APCwt and Fen1 mutant binding/density of APCwt
and Fen1 wild-type) × 100 = percent bound)]. The experiment was repeated twice.
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APC domains and the ability to sense DNA damage are reminiscent
of p53, which also acts as a sensor of DNA damage and cellular stress
[50]. Some APC activities are particularly relevant to specific cell
types, as in the development of colon and colorectal cancer, which
is associated with truncation of APC, leading to blockage of LP-BER
and genomic instability.
Fen1, like APC, plays various roles in DNA repair, replication,
and cell cycle control through interaction of different domains with
different proteins or with DNA itself. For instance, Fen1 promotes
elongation and maturation of Okazaki fragments through residues
337-345 and interacts with endonuclease G (EndoG) at residues
349-367, whereas interactions with the DNA repair proteins WRN,
APE1, and NEIL-1 and the Rad9-Rad1-Hus1 checkpoint and PCNA
complex occur at several C-terminal amino acids. The C-terminus
contains the nuclear localization sequences NLS1 and NLS2 that are
positioned between residues 354 and 367. Indeed, like APC and
p53, Fen1 is a highly versatile protein that performs various cellular
functions, depending on its interaction with different proteins.
Both Fen1 and APC are critical to preventing colon and breast can-
cer by sensing DNA damage and promoting LP-BER. The evidence
for involvement in colon cancer prevention is extensive: APC plays a
tumor suppression role that is lost as APC is truncated at amino acids
1441-2077 that block DSB DNA repair [51]. The evidence for pre-
venting breast cancer is more subtle but, nevertheless, compelling. Epi-
genetic inactivation of APC due to DNA methylation is frequently
present in both breast cancer cell lines and breast cancer tissue. Epi-
genetic inactivation of APC affects its tumor suppression function. It
has been observed that disruption of the APC/β-catenin pathway play
an important role in breast cancer, whereas loss of APC expression
and up-regulation of β-catenin have been described in human breast
cancer and breast cancer cells [52,53]. We have previously demon-
strated that genotoxic agents (DNA alkylating agents) transcriptionally
induce APC level [32]. However, the function of nuclear APC has not
been elucidated. We predict that nuclear APC has a negative regula-
tory role in DNA repair. The increased cytosolic level of APC results
in increased Fen1 interaction thereby reducing Fen1 translocation
to the nucleus, which is essential for its role in LP-BER. However,
increased nuclear APC level depletes the freely available nuclear Fen1
by binding to it and leads to impaired LP-BER.
Although genetic mutations of APC or β-catenin are rarely observed
outside colonic tumors [14,54–56], loss of heterozygosity at APC
locus has been observed in 63% of breast cancer cell lines [57]. In
another study, 6% alteration in APC protein level in breast tumors
was detected [53]. A targeted constitutive mutation in the Apc tumor
suppressor gene has been shown to cause mammary, but not intestinal,
tumorigenesis [58]. However, APC can interact with numerous pro-
teins critical for genome stability; modification of these interactions is
likely to play major roles in carcinogenesis including breast cancer [59].
In fact, results with a hypomorphic mutant allele of Apc (Apc1572T) in
mouse suggests that APC regulates specific dosages of Wnt/β-catenin
signaling activity differentially, thus affecting tissue homeostasis and
initiating breast tumorigenesis [59]. Also, a model in which K14-cre-
mediated Apc heterozygosity (in which Apc exon 14 is flanked by
loxP sequences) implicates APC in the development of mammary
Figure 8. Fen1(NLS2mut) retains 5′-flap endonuclease and 5′-3′ exonuclease activities. (A) Schematic of protocol for the pull-down of
Fen1 proteins from the TNT reaction mixture. (B) Western blot analysis of Fen1 proteins synthesized by TNT. (C) Autoradiogram depict-
ing 5′-flap endonuclease activity. Equal amounts of TNT-synthesized proteins were used in these assays. Purified Fen1wt protein at
0.2 nM was used as a positive control. A 11-nt cleaved endonuclease product is shown with an arrow. (D) Autoradiogram depicting
5′-3′ exonuclease activity. A 1-nt cleaved exonuclease product is shown with an arrow. Equal amounts of TNT-synthesized proteins were
used in these assays. Data are representative of three different determinations.
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adenocarcinoma in APCmin/+ mice [60]. Notably, these mutations are
located in the C-terminus required for interaction with Fen1 and well
beyond the MCR region of Apc mutations frequently found in mouse
gastrointestinal tumors [61–64]. Mutated Apc, whether frame-shifted
or truncated, typically retains the DRI domain (amino acids 1245-
1273) and remains capable of interacting with Fen1 to block LP-BER.
Furthermore, Oncomine data analysis and our immunohisto-
chemical analysis data clearly indicate an increased association of
APC with Fen1 in breast carcinoma in comparison to normal breast
tissue. We have shown that, after treatment with environmental car-
cinogens, Fen1 [37] and APC expression [32,36,65,66] increase in
spontaneously immortalized normal human breast epithelial cells,
human colon cancer cells, and mouse embryonic fibroblasts. Because
both Fen1 and APC are tumor suppressors [14,20,67], an increase in
their expression would be expected to protect against tumorigenesis;
however, this does not seem to be the case in breast and lung tumor-
igenesis. Instead, the increased expression of Fen1 in breast and lung
cancer cells may reflect either increased proliferation of cancer cells or
a response to increased DNA damage [68,69]. Therefore, it is possi-
ble that the interaction of Fen1 and APC not only blocks LP-BER
but also impairs each other’s tumor suppressor functions involved in
neoplastic transformation.
In conclusion, these results demonstrate that APC and Fen1 partici-
pate in DNA repair in both cultured cells and primary cultures and
provide the first direct evidence for how carcinogens promote Fen1
retention in the cytoplasm as well as sequestration in the nucleolus that
results in reduced LP-BER and accumulation of abasic lesions that
can accelerate the malignant transformation. These studies form the
framework for development of novel agents that target APC/Fen1 inter-
action and the BER pathway for the prevention of breast and colorectal
cancer development.
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